OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
4,74Â US$
arrow_upward
+0,64%(+0,030) 1D
9. okt., 16.00.00 GMT-4 · USD
search
Alle symboler
| Symbol | Pris | Ændring | Ændring i % |
|---|
insights_autoGenererer vigtig indsigt for OPHLY...
Ă…bn
4,71Â US$
Høj
4,78Â US$
Lav
4,71Â US$
Markedsværdi
1,13Â bio.
Gns. vol.
58,90Â t
Volumen
37,66Â t
Højeste i 52 uger
5,75Â US$
Laveste i 52 uger
3,81Â US$
Beta
0,21
Aktier i omløb
1,50Â mia.
Antal ansatte
4Â t
Ă…bn
4,71Â US$
Høj
4,78Â US$
Lav
4,71Â US$
Markedsværdi
1,13Â bio.
Gns. vol.
58,90Â t
Volumen
37,66Â t
Højeste i 52 uger
5,75Â US$
Laveste i 52 uger
3,81Â US$
Beta
0,21
Aktier i omløb
1,50Â mia.
Antal ansatte
4Â t
Nyhedshistorier
Fra webkilder og nyhedspartnere
TipRanks
·
for 1 dag siden
Ono Pharma Advances Pediatric Epilepsy Trial, Bolstering Long-Term Growth Story
Stock Titan
·
for 2 dage siden
A Phase 3 Graves’ disease drug is part of a deal that could pay Biohaven up to $100 million.
Profil
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Om Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
Administrerende direktørGyo Sagara | Gyo Sagara
Ansatte4,21Â t
Grundlagt1717
HovedsædeOsaka, Osaka, Japan
Sektor-
Websiteono-pharma.com